Background: Neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) have been demonstrated to be prognostic biomarkers in various cancers, including non-small cell lung cancer (NSCLC). However, little has been known about these two ratios for a specific population of NSCLC harboring active epidermal growth factor receptor (EGFR) mutation.
Introduction
Epidermal growth factor receptor (EGFR) mutation status divides non-small cell lung cancer (NSCLC) into two genetic subsets, NSCLC with positive EGFR mutation and NSCLC with wild-type EGFR. For the former subset, EGFR tyrosine kinase inhibitors (EGFR-TKIs) provide better efficacy and longer survival than conventional cytotoxic chemotherapy. Thus, exclusively for these selected patients, EGFR-TKIs are prioritized over conventional chemotherapy. However, these drugs are not always effective for them. Overall response rate ranged 60-80%. Many patients experienced tumor progression 9 -13 months after initiation of EGFR-TKIs [1] [2] [3] [4] [5] [6] .
Patient's systemic inflammatory response (SIR) plays an adverse role in development and prognosis of cancers [7] [8] [9] . Neutrophils, lymphocytes and monocytes are important for the cancer-induced SIR [10, 11] . These three types of circulating cells represent the patients' SIR. Their peripheral absolute counts can predict prognoses of various malignancies, including NSCLC. According to a Japanese analysis of 388 chemonaive NSCLC with stage IIIB or IV, pretreatment elevated neutrophil count was significantly associated with shorter overall survival (OS) and progression-free survival (PFS). However, this study failed to show any association between prognosis and lymphocyte or monocyte count [12] . On the other hand, another Japanese multivariate analysis of 237 node-negative NC-SLC demonstrated that a preoperative peripheral lymphocyte count was an independent prognostic factor for OS rate, but the neutrophil count was not [13] . A Chinese multivariate analysis of 142 patients with NSCLC who had underwent lobectomy, lymph node dissection and adjuvant chemotherapy also detected preoperative lymphocyte count, but not neutrophil count, as an independent prognostic factor of disease-free survival [14] . These two studies considered that peripheral lymphocyte count was associated with vascular or lymphatic invasion [13, 14] . Regarding peripheral monocyte count, in a Chinese analysis of 370 patients who had received platinum-based doublet for pre-
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World J Oncol. 2017;8(6):180-187 viously untreated metastatic NSCLC, monocyte count was an independent prognostic factor for PFS and OS [15] . Recently, there has been increasing evidences of the prognostic value of combined scoring systems based on the SIR. Especially, neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) are easily calculated from leukocyte count and differentiation. Elevated NLR [16] [17] [18] and decreased LMR [15, 19] have been demonstrated to be associated with poor prognosis in various cancers, including advanced NSCLC. However, little has been known about these two ratios for a specific genetic subset of EGFR mutant NSCLC.
In this study, we evaluate the prognostic value of NLR and LMR in patients with EGFR mutant NSCLC.
Methods
This study was retrospective and single institutional. We collected the following patients: 1) patients who started EGFRTKIs monotherapy between October 2007 and February 2017, 2) histologically or cytologically proven NSCLC, and positive EGFR mutation status confirmed by the peptide nucleic acid-locked nucleic acid PCR clamp method by LSI Medience Cooperation (Tokyo, Japan) [20] , 3) c-stage IIIA-B, IV or post-surgical recurrence, based on the 7th TNM classification of lung cancer by the Union for International Cancer Control (UICC) [21] , 4) patients who received blood test within 1 week before the initiation of EGFR-TKIs. In Japan, gefitinib, erlotinib and afatinib were approved for NSCLC in July 2002, October 2007 and January 2014, respectively. EGFR mutation tests became covered by insurance in June 2007. The definitions of overall response rate (RR), disease control rate (DCR), PFS and OS in this study followed those of our previous studies [22, 23] . When RR, DCR and PFS were calculated, sequential change from a TKI to another TKI due to adverse effects was arbitrarily defined as one regimen treatment in this study. When we calculated creatinine clearance (Ccr) by means of Cockcroft-Gault equation, we added 0.2 mg/dL on serum creatinine values determined by the enzymatic method [24] . Peripheral venous blood (approximately 2 mL) was collected into a sterile ethylene-diamine-tetra-acetic acid (EDTA) tube. Hematological parameters were analyzed using hematology analyzers (Sysmex XE-2100 until 2012, and thereafter Sysmex XE-5000; Sysmex, Kobe, Japan). NLR and LMR were obtained by dividing pretreatment venous absolute circulating neutrophil count by lymphocyte count, and venous absolute circulating lymphocyte count by monocyte count, respectively. The data cut-off was September 1, 2017. The Osaka Police Hospital Ethics Committee approved this study (number 685), and waived the requirement for informed consent because de- NLR for NSCLC With EGFR Mutation World J Oncol. 2017;8(6):180-187 identified data were retrospectively collected. We described the continuous, categorical and survival variables as the mean ± standard deviation (SD), frequency, median (95% confidential intervals (CIs)), respectively. We used Fisher's exact and Mann-Whitney tests for comparison of the relative frequencies and continuous variables that were not normally distributed, respectively. Using receiver operating characteristic (ROC) curve and Youden index, we selected the optimal cut-off values of NLR and LMR, and then divided our patients into two groups. We arbitrary defined complete and partial responses of EGFR-TKIs as the outcome variables of ROC analysis. The results of ROC analyses were expressed as sensitivity, specificity, area under the curve (AUC) with 95% CI. We used Kaplan-Meier method to evaluate PFS and OS, and compared two groups by log-rank test.
To investigate independent prognostic factors, we used Cox proportional hazard analyses. After the univariate analysis, only variables with P-value < 0.1 were used in the multivariate analysis. The results were described as hazard ratios (HR) and 95% CI. P-value < 0.05 was defined as statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [25] .
Results
We collected 152 patients for this study. At the time of data-cut off, 85 patients were dead, 39 still alive and 28 lost to followup. As for the first TKI treatment, 15 patients still continued TKI, while the other 137 discontinued TKI because of PD in 84, adverse effects in 20, deteriorated comorbidity or general condition in 17, change regimens from EGFR-TKI to cytotoxic drugs before PD in 5, patients' refusal in 3, transfer to other hospitals in 6 and unidentified death in 2. Eleven patients changed TKIs mainly due to adverse effects. As the optimal cut-off points of NLR and LMR, ROC curves defined 2.11 (sensitivity 0.75, specificity 0.42, AUC 0.54, 95% CI 0.44 -0.64) and 5.09 (sensitivity 0.83, specificity 0.39, AUC 0.60, 95% CI 0.51 -0.69), respectively.
High NLR group (NLR ≥ 2.11) included more patients with bone metastases (45% vs. 20%, P < 0.01) and severe Eastern Cooperative Oncology Group performance status (ECOG PS) (P < 0.01) than low NLR group (NLR < 2.11). High LMR group (LMR ≥ 5.09) was characteristics of more female (74% vs. 57%, P = 0.047), less frequent bone metastases (21% vs. 43%, P = 0.01), better PS (P < 0.01) than low LMR group (LMR < 5.09) ( Table 1) . Patients with low NLR were more likely to receive further line chemotherapy (76% vs. 58%, P = 0.03). RR were significantly higher in high LMR group than in low LMR group (76.6% vs. 54.3%, P = 0.01). DCRs were significantly higher in low NLR (92.6% vs. 73.5%, P < 0.01) and high LMR (93.6% vs. 74.3%, P < 0.01) groups than in high NLR and low LMR groups ( Table 2 ). OS of low NLR (OS, 38.6 vs. 24.1 months in median, P < 0.01) and high LMR (OS, 39.4 vs. 26.4 months, P < 0.01) groups were significantly longer than those of high NLR and low LMR groups (Fig. 1) . 
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However, PFS of low NLR (PFS, 15.9 vs. 10.1 months in median, P = 0.04) group was significantly longer than those of high NLR group, while there was no statistically significant difference in PFS according to LMR (Fig. 2) . Univariate analyses detected ECOG PS 0 -1, higher Ccr, higher sodium concentration, lower lactate dehydrogenase (LDH), lower C-reactive protein (CRP), lower NLR and higher LMR as prognostic factors for longer OS; no distant metastasis, ECOG PS 0 -1, body mass index (BMI) ≥ 18.5, EGFR-TKI introduction in first-line setting, treatment with erlotinib or afatinib, higher Ccr, higher sodium concentration, lower LDH, lower CRP, lower NLR and higher LMR as predictive factors for longer PFS (Table 3 ). The subsequent multivariate analyses found lower NLR (HR 1.07, 95%CI: 1.01 -1.14; P = 0.03) as an independent prognostic factor for longer OS, in addition to ECOG PS 0 -1, first-line introduction of EGFR-TKI, higher sodium concentration and lower LDH. However, LMR was not detected as a significant prognostic factor for OS (Table 4) . Neither NLR nor LMR was selected as a significant prognostic factor for PFS (Table 5) .
Discussion
This study was a comprehensive evaluation of two biomarkers and prognosis in patients with EGFR mutant NSCLC treated 
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with EGFR-TKIs. To our knowledge, there were only four studies and one study that had investigated association of NLR [26] [27] [28] [29] and LMR [30] with prognosis, respectively (Table 6) . NLR is an independent prognostic factor for OS of those selected population. Our survival comparisons and multivariate analyses demonstrated that higher NLR was associated with poorer OS, and were consistent with previous three studies [26] [27] [28] . On the other hand, despite of significantly longer OS in patients with LMR ≥ 5.09, our multivariate analysis failed to detect LMR as a significant prognostic factor for OS. This result was different from the previous larger-scaled study [30] . Our study scale might be insufficient to evaluate LMR.
Both NLR and LMR are still controversial as prognostic factors for PFS of EGFR-TKI treatment. In our survival comparisons, PFSs of patients with NLR ≥ 2.11 and LMR < 5.09 were significantly shorter than those of patients with NLR < 2.11 and LMR ≥ 5.09, respectively. However, our multivariate analyses did not detect NLR and LMR as independent prognostic factors for PFS. As an independent prognostic factor for shorter PFS, NLR ≥ 3.5 [27, 28] and NLR ≥ 5 [26] were demonstrated by previous studies. However, a Korean study failed to demonstrate NLR ≥ 3 as a significant prognostic factor [29] . On the other hand, a Taiwan study found that high baseline LMR was an independent prognostic factor for PFS of first-line TKIs [30] , which was contrary to ours. Between the Taiwan and our studies, there seemed to be some differences in and TKI line setting (first vs. second or later line), while the Taiwan study detected LMR, the 1-month-to-basline ratio of LMR, EGFR mutation (common vs. uncommon) and distant metastases (0 -2 vs. > 2). Thus, there is no established view on these two biomarkers as prognostic factors for PFS. Our study included some limitations. First, we are afraid that our study was too small to find these two biomarkers as significant factors. Especially, our study underestimated LMR as a prognostic factor for OS. Second, our study might include case bias because of a single-centered and retrospective study. Multi-centered, prospective and larger-sized studies are ideal for such a specific cancer population.
Conclusions
This study demonstrated that elevated NLR is an independent prognostic factor for poor survival of patients with EGFR mutant NSCLC. NLR is a useful and simple biomarker for these patients, while LMR requires further studies as a significant 
